Novo Nordisk A/S
F:NOVC

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
F:NOVC
Watchlist
Price: 90.7 EUR -1.52% Market Closed
Market Cap: 203.5B EUR

EV/EBIT
Enterprise Value to EBIT

12.7
Current
25.6
Median
16.5
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
12.7
=
Enterprise Value
1.7T DKK
/
EBIT
132.7B DKK
All Countries
Close
Market Cap EV/EBIT
DK
Novo Nordisk A/S
F:NOVC
1.6T EUR 12.7
US
Eli Lilly and Co
NYSE:LLY
997.6B USD 39
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
US
Johnson & Johnson
NYSE:JNJ
494.8B USD 20.9
CH
Roche Holding AG
SIX:ROG
263.6B CHF 13.9
UK
AstraZeneca PLC
LSE:AZN
218.4B GBP 159
CH
Novartis AG
SIX:NOVN
214.5B CHF 15.3
US
Merck & Co Inc
NYSE:MRK
270.7B USD 12
IE
Endo International PLC
LSE:0Y5F
213.9B USD 849.2
US
Pfizer Inc
NYSE:PFE
146.1B USD 10.3
FR
Sanofi SA
PAR:SAN
100.1B EUR 6.6
EBIT Growth EV/EBIT to Growth
DK
Novo Nordisk A/S
F:NOVC
Average EV/EBIT: 1 712.8
12.7
0%
N/A
US
Eli Lilly and Co
NYSE:LLY
39
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.9
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
159
23%
6.9
CH
Novartis AG
SIX:NOVN
15.3
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5
FR
Sanofi SA
PAR:SAN
6.6
15%
0.4

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
12.9
2-Years Forward
EV/EBIT
12.9
3-Years Forward
EV/EBIT
12.1